Cargando…

CD73: A Promising Biomarker in Cancer Patients

Detalles Bibliográficos
Autores principales:	Turiello, Roberta, Pinto, Aldo, Morello, Silvana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751688/ https://www.ncbi.nlm.nih.gov/pubmed/33364969 http://dx.doi.org/10.3389/fphar.2020.609931

Ejemplares similares

Exacerbation of Allergic Airway Inflammation in Mice Lacking ECTO-5′-Nucleotidase (CD73)
por: Caiazzo, Elisabetta, et al.
Publicado: (2020)

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
por: Capone, Mariaelena, et al.
Publicado: (2020)

CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

The Ecto-5’-Nucleotidase/CD73 Inhibitor, α,β-Methylene Adenosine 5’-Diphosphate, Exacerbates Carrageenan-Induced Pleurisy in Rat
por: Caiazzo, Elisabetta, et al.
Publicado: (2019)

Thrombo-Inflammation: A Focus on NTPDase1/CD39
por: Morello, Silvana, et al.
Publicado: (2021)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018)

Association of the ADORA2A receptor and CD73 polymorphisms with epilepsy
por: Shi, Nan-Rui, et al.
Publicado: (2023)

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020)

Unveiling the Role of Ecto-5′-Nucleotidase/CD73 in Astrocyte Migration by Using Pharmacological Tools
por: Adzic, Marija, et al.
Publicado: (2018)

Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
por: Gardani, Carla Fernanda Furtado, et al.
Publicado: (2023)

A2A Receptor Contributes to Tumor Progression in P2X7 Null Mice
por: De Marchi, Elena, et al.
Publicado: (2022)

Upregulated Linc01836 in Serum Promisingly Serving as a Diagnostic and Prognostic Biomarker for Colorectal Cancer
por: Shen, Lei, et al.
Publicado: (2022)

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
por: Kurago, Zoya, et al.
Publicado: (2023)

The Roles of CD73 in Cancer
por: Gao, Zhao-wei, et al.
Publicado: (2014)

The Clinical Significance of CD73 in Cancer
por: Bach, Niklas, et al.
Publicado: (2023)

CD73-Adenosine A(1)R Axis Regulates the Activation and Apoptosis of Hepatic Stellate Cells Through the PLC-IP(3)-Ca(2+)/DAG-PKC Signaling Pathway
por: Liu, Zhenni, et al.
Publicado: (2022)

RIPK2: a promising target for cancer treatment
por: You, Jieqiong, et al.
Publicado: (2023)

The adenosinergic system in cancer: Key therapeutic target
por: Sorrentino, Rosalinda, et al.
Publicado: (2013)

Targeting copper metabolism: a promising strategy for cancer treatment
por: Kong, Ruimin, et al.
Publicado: (2023)

In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5
por: Beggiato, Sarah, et al.
Publicado: (2018)

CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer
por: Chen, Qiangda, et al.
Publicado: (2020)

CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism
por: Liu, Weishuai, et al.
Publicado: (2022)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer
por: Buss, Julieti Huch, et al.
Publicado: (2018)

Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review
por: Zhao, Maoyuan, et al.
Publicado: (2022)

The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis
por: Lin, Lanmei, et al.
Publicado: (2022)

Promising Antineoplastic Actions of Melatonin
por: Favero, Gaia, et al.
Publicado: (2018)

Targeting glycolysis in non-small cell lung cancer: Promises and challenges
por: Xu, Jia-Qi, et al.
Publicado: (2022)

Lack of Ecto-5′-Nucleotidase Protects Sensitized Mice against Allergen Challenge
por: Caiazzo, Elisabetta, et al.
Publicado: (2022)

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
por: Harvey, Jerry B., et al.
Publicado: (2020)

The distinct role of CD73 in the progression of pancreatic cancer
por: Zhou, Liangjing, et al.
Publicado: (2019)

The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment
por: Sun, Pengcheng, et al.
Publicado: (2022)

CD39/CD73/A2AR pathway and cancer immunotherapy
por: Xia, Chenglai, et al.
Publicado: (2023)

Natural products modulate cell apoptosis: a promising way for treating endometrial cancer
por: Zhou, Xin, et al.
Publicado: (2023)

Nanocurcumin: A Promising Candidate for Therapeutic Applications
por: Karthikeyan, Adhimoolam, et al.
Publicado: (2020)

Clofazimine: A Promising Inhibitor of Rabies Virus
por: Wu, Jiajing, et al.
Publicado: (2021)

Berberine: A Promising Treatment for Neurodegenerative Diseases
por: Cheng, Ziqian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h3uulfacundv1qng85kb651dj6